TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07675135: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy Followed by an Open-label Extension

Sponsor: Harmony Biosciences Management, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 258 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$7,637,328

Rescue Site Savings

+$5,044,408

Unlock Full NCT07675135 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07675135 Rescue Dossier →